DC-102
PTC-M, Dr.Cure’s proprietary therapeutic adjuvant can be applied first to colon cancer and liver cancer and then expanded to various solid cancers as a universal radiosensitizers.
Radiation Therapy Efficacy in Liver Cancer
Approximately 4.5 times greater therapeutic efficacy compared to the control group.
Establishing Radiosensitizer Technology for Liver Cancer Cells
Evaluation of oxygen-generating capacity of manganese oxide.
Approximately 3.8 times more oxygen was generated compared to the initial level.
Hypoxia Induction and Key Protein Analysis
Hypoxia was induced in liver cancer cells using a hypoxia chamber.
Treatment with manganese oxide nanoparticles reduced the hypoxic regions.
Expression of the hypoxia-related protein HIF-1α was decreased.
Treatment with manganese oxide nanoparticles reduced the hypoxic regions.
Expression of the hypoxia-related protein HIF-1α was decreased.
Validation of Radiotherapy Efficacy Using Manganese Oxide Liposomes
HepG2 liver cancer cells were treated with manganese oxide liposomes and irradiated.
Under hypoxic conditions, compared to normoxia, a decrease in live cells (green) and an increase in dead cells (red) were observed.
Under hypoxic conditions, compared to normoxia, a decrease in live cells (green) and an increase in dead cells (red) were observed.
